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Abstract
Background: Hepatic steatosis (HS) has been associated with obesity and metabolic syndrome (MS), conditions
carrying a high risk of coronary artery disease. We aimed to determine whether HS was an independent factor of
atherogenic risk beyond its association with MS and its components.
Methods: We assessed the circulating levels of the heat shock protein-70 (HSP-70), a chaperone involved in
inflammation, endoplasmic reticulum stress and apoptosis at liver and endothelial level and the gamma-glutamyl
transferase activity (g-GT) correlating them to carotid intima-media thickness (IMT), along with lipid profile, HOMA,
C-reactive protein, fibrinogen, ferritin, adiposity type as well as spleen volume in 52 obese pts with grade 1, 128
with grade 2, and 20 with grade 3 of HS evaluated by sonography.
Results: Patients with different grade of HS demonstrated overlapping HSP-70 levels; similarly performed obese
subjects regarding IMT. Using multiple regression analysis, IMT was predicted by age, visceral adiposity and by
HOMA (b = 0.50, p < 0.0001, b = 0.30, p = 0.01 and b = 0.18, p = 0.048 respectively, while the severity of HS was
predicted by visceral and subcutaneous adiposity and HOMA (b = 0.50, p < 0.0001 and b = 0.27, p = 0.001 and
b = 0.18, p = 0.024, respectively).
Conclusion: In our series of patients with normal or mild elevation of g-GT, the severity of HS does not entail
higher IMT, which may be linked to MS stigmata.
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Background
Unclassified nonalcoholic fatty liver disease (NALFD) or
hepatic steatosis (HS), a further expression of the meta-
bolic syndrome (MS) [1], easily detected by ultrasound
(US), is highly prevalent condition in obese individuals.
Free fatty acids (FFAs) have been shown to be the major
contributor to triglyceride accumulation in hepatocytes
observed in NAFLD [2]. The excessive supply of FFAs
toward the liver leads per se to hepatic insulin resistance
(IR) and endoplasmic reticulum stress (ERS) [3]. Heat
shock proteins (HSPs) function as intra-cellular chaper-
ones. The unfolded protein response (UPR), a fundamen-
tal cellular process triggered by ERS, is aimed at initiating
programmed cell death. The UPR is activated and dysre-
gulated in NAFLD [4]. On the other hand, chronic ERS
activates UPR in arterial endothelium in regions of sus-
ceptibility to atherosclerosiss [5]. ERS activation partici-
pates in fat deposition in the liver [6] and could directly
induce IR. Insulin-resistant state in turns increases the
plasma FFAs flux [7]. The best known member of HSP is
the stress-inducible form of HSP-70, i.e., HSP-72, also
called HSPA1A. The HSP-70 expression decreases with
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bit fat accumulation in liver and the Hsp70 expression is
down-regulated [9]. These data were confirmed in obese
Zucker rats with HS [10]. Ischemic preconditioning by
increasing HSP-72 protects steatosic livers [11]. In wild-
type mice, refractory to high-fat dietary-induced effects, a
marked increase in HSP-72 levels in liver was evidenced
[12]. HSP-70 can be produced in the liver and spleen as
acute phase reactant and released into circulation to
facilitate the disposal of dying cells [13]. Low-grade
chronic inflammation, which is characterized by
increased serum concentrations of interleukin-6 (IL-6)
and enlarged spleen volume [14] likely due to dendritic
cells (DCs) mobilization, is contributing factor in devel-
oping the more severe form of HS in obese patients.
HSPs have been reported to play important roles in acti-
vation and maturation of DCs [15]. Moreover, the con-
centration of HSP-70 is inversely correlated to IL-6 [16].
Gamma-glutamyltransferase (g-GT) is a subclinical clue
of IR [17], even though the prevailing interpretation is
that its high serum levels represent just an early evidence
of oxidative stress. Its mechanism relies on the fact that
cellular g-GT is closely linked to metabolism of glu-
tathione (GSH), the most abundant intracellular antioxi-
dant [18]. Depletion of GSH affects the synthesis of HSP-
70 in Hep G2 cells [19]. Finally, HS is characterized by
elevated levels of g-GT [20], which is also a predictor of
coronary artery disease (CAD) [21].
The direct contribute of HS to early atherosclerosis,
evaluated as increased intima media thickness (IMT),
is controversial. Against this background, we thought
of exploring the behavior of HSP-70 and g-GT, mole-
cules playing a key role in both liver and endothelium,
in obese patients with different entity of hepatic fat
storage in relationship to carotid IMT in order to
establish whether NAFLD was an independent factor
of atherogenic risk beyond its association with MS and
its components. Contextually, we tried to find out
whether serum levels of HSP 70 and g-GT correlated
to metabolic indices, anthropometric measures, type of
adiposity, inflammatory markers [22], and finally
immune status, focusing our attention on liver-spleen
axis [23].
Methods
This cross-sectional study was performed enrolling out-
patients from September 2009 through February 2011.
Clinical investigation, blood samples and ultrasound
(US) parameters were strictly carried out within two
months. Protocol was consistent with the principles of
the Declaration of Helsinki and participants gave their
informed consent, according to our Medical School
committee approval.
Inclusion criteria
Two hundred obese patients with at least another criter-
ium of those below specified clustering MS, diagnosed
suffering from NAFLD by evaluating the liver/kidney
difference of brightness at US, with or without elevated
alanine aminotransferase (ALT) or g-GT, were studied.
They were allocated in three groups according to the
severity of HS scored at US.
Obese individuals were selected to participate in this
study before being given weight control indications. The
degrees of obesity was established on the basis of body
mass index (BMI) cut-off points of 30-34.9, 35-39.9 and
>40 kg/m
2, respectively. Central obesity was identified by
waist circumference (WC) >102 cm in men or >88 cm in
women, measured at the midpoint between the lower
border of the rib cage and the iliac crest. Presence of type
2d i a b e t e sm e l l i t u s( T 2 D )w a sa s s e s s e db yaf a s t i n g
plasma glucose ≥126 mg/dl (≥7.0 mmol/l), confirmed on
a separate day or a random glucose level of 200 mg/dL or
higher and classic symptoms of T2D (polyuria, polydip-
sia, polyphagia, weight loss) or HbA1c ≥6.5%. Impaired
fasting glucose (IFG) was set with a fasting plasma glu-
cose between 100 and 125 mg/dl. MS was defined
according to the revised Adults Treatment Panel III
(2001), and three or more criteria were considered:
plasma glucose concentration of at least 100 mg dL-
1,
WC >102 cm in men and >88 cm in women, serum high-
density lipoprotein (HDL)-cholesterol concentration
<40 mg dL
-1 inm e na n d< 5 0m gd L
-1 inw o m e n ,b l o o d
pressure of at least 130/85 mm Hg, and serum triglycer-
ide concentration of at least 150 mg dL
-1. The subjects
were classified as insulin resistant according to a strin-
gent homeostasis model assessment of IR (HOMA) set-
ting the cut-off at 2.
E x c l u s i o nc r i t e r i aw e r eah istory of previous acute
CAD in course of T2D, infectious chronic diseases
including hepatitis B and C, neoplastic and/or haemato-
logical diseases, autoimmune and storage diseases,
unstable medical conditions, drugs inducing HS (ster-
oids and amiodarone) and prior use of medications
known to affect inflammation (aspirin), blood lipids (sta-
tins) or insulin sensibility (metformin) and finally baria-
tric surgery. Alcohol abuse was ruled out, according to
the DSM-IV diagnostic criteria, by means of screening
tests such as MAST (Michigan Alcohol Screening Test)
and CAGE (Cut down, Annoyed, Guilty, and Eye
opener), as well as random tests for blood alcohol con-
centration and the use of a surrogate marker, e.g., Mean
Corpuscular Volume.
Instrumental measurements
They were performed using GE vivid systems (General
Electric, Milan Italy). Transverse scanning was performed
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a 11 MHz linear probe and visceral adipose tissue (VAT)
using a 4 MHz convex probe. The SAT was defined as
the thickness between the skin-fat interface and the linea
alba, avoiding compression, and the VAT was defined as
the distance between the anterior wall of the aorta and
the internal face of the recto-abdominal muscle perpen-
dicular to the aorta, measured 1 cm above the umbilicus.
W h e nt h ea o r t i cw a l l sw e r en o tv i s u a l i z e da st h e yw e r e
obscured by bowel gas, the doppler scan was used.
Spleen longitudinal diameter (SLD) was performed by
postero-lateral scanning [14]. The classification of sever-
ity of HS or entity of hepatic fat storage was based on the
following scale of hyperechogenity: 0 = absent, 1 = light,
2 = moderate, 3 = severe, pointing out the difference
between the densities of the liver and the right kidney
[24]. Technically, echo intensity can be influenced by
many factors, particularly by gain intensity. To avoid con-
founders that could modify echo intensity and thus bias
the comparisons, the mean brightness levels of both liver
and right kidney cortex were obtained on the same longi-
tudinal sonographic plane. The common carotid, the car-
otid bulb and the internal carotid near and far wall
segments were scanned bilaterally. Subjects were exam-
ined in the supine position with the head turned 45° con-
tra-lateral to the side of scanning. Images were obtained
in longitudinal section, with a single lateral angle of iso-
nation, optimizing the imagef o rt h ef a rw a l l .I M Tw a s
defined as the distance between the lumen-intima and
the media-adventitia ultrasound interfaces. Measure-
ments were performed off-line and consisted of six man-
ual measurements at equal distances along 1 cm on the
far wall of the common carotid. Left and right IMT were
averaged.
The systolic/diastolic blood pressure (SBP/DBP) was the
average of three consecutive readings taken by the physi-
cian during the day, during usual practice hours, and after
subjects had rested for 5 min in the sitting position. Dur-
ing the 30-minute preceding the measurement, subjects
were required to refrain from smoking or consuming caf-
feine. Patients on antihypertensive therapy maintained a
balanced therapeutic regimen based on calcium channel
blockers or ACE inhibitors throughout the study.
Laboratory data
The HSP70 determination was made on sera stored at
-70°C using a high sensitivity EIA kit by Enzo Life
Sciences International, Inc., PA USA. This is the only
commercially available kit sensitive enough to quantify
HSP-70 in serum and plasma samples, fully validated in
stressed and non-stressed serum and plasma samples and
able to measure HSP-70 with negligible reactivity with
other HSP family members. The absorbance was read at
450 nm with results in 4/5 hours. The sensitivity range
was 0.09-12.5 ng/ml; the sensitivity or limit of detection
of the assay was 0.09 ng/mL (90 pg/mL). The sensitivity
was determined by interpolation at 2 standard deviations
above the mean signal at background (0 ng/mL) using
data from 7 standard curves. The intra-assay precision
was determined by assaying 20 replicates of three buffer
controls containing Hsp70 in a single assay with a CV
ranging from 3.9 to 11.4%. The inter-assay precision was
determined by measuring buffer controls of varying HSP-
70 concentrations in multiple assays over several days
with a CV ranging from 12.8% to 19.1%. Forty one appar-
ently healthy, lean subjects, without HS at US were
selected to set our normal values of serum HSP-70.
CRP values were determined by the ELISA test, with
reference values between 0.3 and 8.6 mg/L in healthy men
and between 0.2 and 9.1 mg/L in healthy women (Bio-
Check, Inc CA, USA). Total cholesterol, high-density lipo-
protein (HDL) cholesterol, and triglyceride concentrations
were assessed by enzymatic colorimetric methods; ALT
and g-GT by the enzymatic UV method; and glucose con-
centration by a hexokinase method. The fasting insulin
level was measured by an immunoradiometric assay with a
BioSource INS-IRMA Kit (BioSource, Belgium). Its coeffi-
cient of variation was 1.6% to 2.2% for the intra-assay and
6.1% to 6.5% for the inter-assay. Fibrinogen was deter-
mined using an ELISA kit by United States Biological, TX,
USA.
Blood alcohol concentration was measured by a fluores-
cence polarization immunoassay technology using an
Abbott kit on AxSYM Instrument, Abbott Park, Illinois.
HOMA was assessed by the formula: fasting insulin
(μU/mL) × fasting glucose (mg/dL)/405.
Statistics
Age, BMI, WC, g-GT, ALT, cholesterol, CRP, fibrinogen,
H O M A ,S B P ,D B P ,S A T ,V A T ,S L Da n dI M Tw e r en o t
normally distributed when analyzed by Shapiro-Wilk (S-
W) test, p = 0.001 and were expressed as median plus 25-
75 inter-quartile range (IQR). HDL (S-W, p = 0.20) trigly-
cerides (S-W, p = 0.44) and ferritin (S-W, p = 0.16) data,
derived from a normally distributed population, were
articulated as mean plus SD. The Mann-Whitney (M-W)
U test for independent samples was used when managing
two populations to track differences of medians. When
comparing throughout the three grades of HS, the
ANOVA test with Student-Newman-Keuls test for pair-
wise comparison of subgroups or ANOVA Kruskal-Wallis
test with post-hoc analysis, Conover-Inman test, was
adopted. When the ANOVA analysis was adjusted for age,
BMI and WC, considering them as covariates, the
ANCOVA test was applied. Pearson’s chi square, was used
to look for differences in the classification system. Track-
ing the degree of association between variables the Spear-
man’s rho for non uniform intervals was used. To assess
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prediction of another one, the linear regression analysis
(least squares) was used. At multivariate analysis, the mul-
tiple regression (Backward Stepwise Selection) was
adopted, firstly entering all variables if p =0 . 0 5i n t ot h e
model, and next removing if p = 0.1 the nonsignificant
variables sequentially, with a maximum number of steps
of 15. To avoid multicollinearity, i.e., situations in which
the predictors are correlated to each other to some degree,
the variance inflation factor and tolerance were set to >10
and <0.1, respectively. Similarly, to get sense of which vari-
ables contribute more or less to the regression equation,
the magnitude of standardized coefficient beta (b) was cal-
culated. The Factor Analysis was applied to detect the
structure in the relationships among variables, selecting a
subset of variables having the highest correlations with the
principal component factors. The Cattell Scree plot, with
relative eigenvalues, was performed to screen the real fac-
tors. Extraction of the main components amounted to a
variance maximizing (varimax) the rotation of the original
variable space. To evaluate intra/inter-observer variability
of the measurements, the mean difference in the measure-
ments of the observers was first calculated. Next, the con-
cordance correlation coefficient (rc), which measures
precision and accuracy, was adopted to evaluate the degree
of pair observations at US, with values >0.8 being consid-
ered indicative of good reliability.
Results
The major part of our obese population evidenced HS of
moderate grade and was characterized by important visc-
eral adiposity, scarce hepatic cytolysis, increased IMT
and progressively increasing frequency of MS throughout
the severity of HS, Tables 1, 2. The median serum con-
centration of HSP-70 in our series of obese patients with
NAFLD was clearly lower than that in controls, i.e., 0.13
(IQR = 0.1-0.54) ng/mL versus 1.09 (IQR = 0.81-2.33)
ng/mL, p < 0.001, Figure 1. There was no significant gen-
der difference when evaluating the serum concentrations
of this chaperone, M-W U test, p = 0.52. At the sub-
groups analysis there was a significant distinction in
HSP-70 levels between the patients with the HS mildest
g r a d ea n dt h em o r es e v e r eo n e ,i . e . ,g r a d e1v e r s u sg r a d e
3, ANOVA K-W, post-hoc analysis Conover-Inman test,
p = 0.03. Indeed, this difference was partially dimmed by
some degree of overlap, Figure 2, and was lost when
HSP-70 values were adjusted for age, BMI and WC (p =
0.60, 0.15, and 0.43, respectively, ANCOVA). The median
concentration of HSP-70 in the three groups of obesity
was equivalent, ANOVA K-W p = 0.23, Figure 3, also
when it was adjusted for the grade of HS (ANCOVA, p =
0.41). At the sub-groups analysis there was a significant
difference in IMT only between the patients with the HS
mildest grade and the moderate one, i.e., grade 1 versus
grade 2, but burdened by an evident overlap, ANOVA K-
W, post-hoc analysis Conover-Inman test, p =0 . 0 2 ,F i g -
ure 4. The g-GT activity, characterized by the major part
of values falling into the upper quartile of normal range
and a higher median in males than in females (M-W U
test, p = 0.049), was comparable in patients with a high
grade and in those with a low grade of HS, ANOVA K-
W, p = 0.1, Figure 5. The concentrations of HDL and fer-
ritin were similar throughout the three subgroups char-
acterized by increasing HS severity (p = 0.16 and 0.35).
As expected, a trend of significance of the levels of trigly-
cerides (p = 0.07) was clear when passing from the group
with the least severe form of HS to the most severe one.
SLD and much better CRP showed a progressive increase
throughout the severity of HS, ANOVA K-W, p =0 . 0 6
and 0.002, respectively. Patients with a hepatic fat deposi-
tion of severe/moderate grade had more features of MS
respect to those with a light grade (Pearson’s chi square,
p = 0.002).
Associations & prediction
At univariate analysis the severity of HS did not predict
HSP-70 levels (b = -0.03, p = 0.7, linear regression).
At multivariate analysis, among the analyzed variables,
HSP-70 was predicted only by the serum HDL levels in
our obese population, i.e., (b =0 . 3 1 ,p = 0.003, multiple
regression, backward stepwise selection).
At univariate analysis, IMT was modestly predicted by
the severity of HS (b = 0.22, p = 0.03, linear regression),
but not by HSP-70 levels (b =0 . 1 6 ,p =0 . 2 4 ,l i n e a r
regression). At multivariate analysis IMT was strongly
predicted by age, sufficiently well by VAT and discreetly
by HOMA (b =0 . 5 0 ,p < 0.0001, b =0 . 3 0 ,p =0 . 0 1a n d
b = 0.18, p = 0.048 respectively, multiple regression
backward stepwise selection), but not by IMT. The
severity of HS was predicted by VAT, SAT and moder-
ately by HOMA (b =0 . 5 0 ,p <0 . 0 0 0 1a n db =0 . 2 7 ,p =
0.001 and b = 0.18, p = 0.024, respectively), multiple
regression, backward stepwise selection. The g-GT activ-
ity was well predicted by ALT activity and serum trigly-
cerides concentration and moderately age (b = 0.31, p =
0.001, b =0 . 2 7 ,p =0 . 0 0 2a n db = 0.225, p = 0.017,
respectively, multiple regression, backward stepwise
selection). As expected, g-GT activity mildly correlated
to HOMA (Spearman’sr h o=0 . 2 8 ,p = 0.043). Mostly
interesting, g-GT activity well predicted SBP (b = 0.30, p
= 0.02, linear regression). SLD was well predicted by
HOMA and SBP (b =0 . 2 0 ,p =0 . 0 4a n db =0 . 2 3 ,p =
0.035, respectively), multiple regression backward step-
wise selection. The severity of HS was not predicted by
ALT and g-GT activity (b =0 . 1 4 ,p =0 . 1 2a n db =0 . 1 2
p = 0.18, respectively, linear regression). CRP levels
were forecasted by BMI (b =0 . 2 3 ,p =0 . 0 2 ,l i n e a r
regression). When analyzing the type of adiposity,
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Patients HS at US HS at US HS at US p
Group score 1 score 2 score 3
n 52 128 20
Age Median years 45 48 49.5 0.27
(IQR) (25-51) (37.5-53.5) (35-55)
BMI Median 37.7 43 49.2 0.005□
(IQR) (33.6-40) (38-46.8) (44-55)
Groups’ difference 1 from 2 1 from 3 2 from 3
WC (f) Median cm 110 124 130 0.003□
(IQR) (104-118) (118-131) (124-138)
Groups’ difference 1 from 2 1 from 3 2 from 3
WC (m) Median cm 116 127 138 0.01□
(IQR) (110-125) (123-136) (134-148)
Groups’ difference 1 from 2 1 from 3 2 from 3
HOMA Median 2.3 3.1 4.08 0.0037□
(IQR) (1.18-3.05) (1.97-4.58) (3.37-5.89)
Groups’ difference 1 from 2 2 from 3 3 from 1
Total Cholesterol 201 180 190 0.2
Median mg/dL (49-222) (156-210) (165-205)
(IQR)
HDL Cholesterol (f) 54.1 ± 11.5 46.6.1 ± 20.2 38.75 ± 16.6 0.047￿
m±SD mg/dL 1 from 2 2 from 1
Groups’ difference
HDL Cholesterol (m) 39.37 ± 16.5 41.9 ± 13.2 45.6 ± 16.6 0.56
m±SD mg/dL
Ferritin (f) 46.2 ± 22.4 61.7 ± 41.1 74.5 ± 22.4 0.43
m±SD ng/mL
Ferritin (m) 197.9 ± 49.6 221 ± 121.7 164.8 ± 23.2 0.72
m±SD ng/mL
Triglycerides 129 ± 89 151 ± 79 204 ± 121 0.07
m±SD mg/dL
SAT cm (f) 2.6 (1.4-2.8) 2.9 (2.6-3.6) 3.5 (3.2-4.3) 0.015□
Groups’ difference 1 from 2 2 from 1 3 from 1
SAT cm (m) 1.9 (1.6-2.4) 2.3 (1.9-2.7) 3.5 (2.2-3.7) 0.035*
Groups’ difference 1 from 2 and 3 2 from 1 and 3 3 from 1 and 2
VAT cm (f) 4.5 (4-6.1) 7.1 (6.1-8) 8.2 (8-8.7) 0.001□
Groups’ difference 1 from 2 2 from 1 3 from 1
VAT cm (m) 6.3 (5.6-6.7) 9.2 (7.8-11) 11.5 (9.2-15) 0.0001*
Groups’ difference 1 from 2 and 3 2 from 1 and 3 3 from 1 and 2
SBP mm Hg 125 (120-140) 130 (120-140) 140 (130-160) 0.0002*
Groups’ difference 1 from 2 and 3 2 from 1 and 3 3 from 1 and 2
DBP mm Hg 85 (80-90) 80 (80-90) 80 (80-95) 0.2
SLD mm 108 (95-118) 111 (100-121) 122 (110-140) 0.06
CRP mg/L 0.3 (0.2-07) 0.8 (0.6-1.5) 1.6 (0.7-2.5) 0.002*
Groups’ difference 1 from 2 and 3 2 from 1 and 3 3 from 1 and 2
Fibrinogen mg/dL 290 (240-320) 300 (260-350) 290 (250-400) 0.56
g-GT U/L 22 (15-36) 25 (19-45.5) 29.5 (27-41) 0.1
ALT U/L 26 (19-40) 30 (27-39) 34 (30-46) 0.17
T2D yes/not 12/40 34/94 7/13 0.33
IFG yes/not 15/37 37/91 9/11 0.42
Hypertension 16/36 47/81 12/8 0.004
yes/not
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(b = 0.36, p = 0.0001 and b =0 . 1 3 5 ,p = 0.18, respec-
tively, linear regression). Accordingly, the factor analysis
revealed as hidden relationships that age was strongly
related to IMT but not to HS severity, that HS corre-
lated to adipose tissue as well as inflammation (CPR)
and finally that the enzymatic activity of ALT and g-GT,
triglycerides and ferritin levels shared same behavior,
Table 3. The intra/inter-observational variability of the
US estimations was not significant, mean difference =
1.9, 2.1, 2.5, 2.3 and 1.7%, and 2.7, 4.8, 4.6, 4.4 and 3.2%
for the bright liver, VAT, SAT, SLD and IMT, respec-
tively, with a rc of 0.91.
Discussion
Researchers have been recently engaged in a seemingly
endless debate about the independent role of NAFLD in
moderately increasing the risk of early atherosclerosis as
a s s e s s e db ys o m eA u t h o r s[ 2 5 , 2 6 ] .O n eh y p o t h e s i sc o u l d
be a direct link between NAFLD and dyslipidemia,
endothelial dysfunction, or oxidative stress [27]. In con-
trast, other researchers demonstrated that NAFLD was
not associated with IMT in people with a high prevalence
of type 2 diabetes mellitus [28,29]. Among metabolically
healthy people, the NAFLD-IMT association was not sig-
nificant after adjusting for cardiovascular risk factors
[30]. HS cannot predict cardiovascular morbidity and
mortality in patients with established CAD [31]. Because
the severity of HS at US does not predict increased IMT
when other risk factors more prominent are included in
the multivariate analysis (age, visceral adiposity and IR),
we can infer that HS, prevalently of moderate grade as
evident in our series, plays a scarce role in determining
atherosclerosis. This aspect is reinforced by the lack of
association between spleen volume, strictly linked to
NAFLD severity [14], and IMT and particularly by the
lack of IMT increase throughout the severity of HS,
meanwhile the MS stigmata showed a completely differ-
ent pattern. Another observation in favor of the scarce
role played by HS in the atherosclerosis process of our
patients is that the entity of visceral adiposity predicted
increased IMT but not the HS grade. Mostly interesting,
g-GT activity was intensively related to ALT activity,
highlighting its hepatic origin or whatever its strict link.
Finally, SLD showed a good relationship to SBP
(increased cell adhesion molecules such as E-selectin,
vascular cell adhesion molecule-1, and intracellular adhe-
sion molecule-1 expression in splenocytes?). Similarly,
researchers are struggling whether NAFLD, determining
local IR, could affect systemic IR. Recent results reveal an
unexpected role for hepatic IL-6 signaling in insulin
action and resistance to limit hepatic inflammation and
to protect from local and systemic IR [32]. In contrast,
the disruption of insulin signaling in the liver is more
relevant to whole body glucose homeostasis than its dis-
ruption in adipose tissue and muscle [33]. In addition,
hepatic insulin signaling regulates the secretion of very
low density lipoprotein and thus lipotoxicity and athero-
genesis [34]. Taking into account that IR was particularly
Table 1 Anthropometric, clinical and laboratory data of the whole population (Continued)
MS yes/not 20/32 70/58 13/7 0.002
IMT Median cm 0.08 (0.06-0.11) 0.11(0.09-0.13) 0.12 (0.10-0.13) 0.02#
Groups’ difference 1 from 2 2 from 1
HS, hepatic steatosis; BMI body mass index; WC waist circumference; HOMA homeostasis model assessment of insulin resistance; SAT subcutaneous adipose tissue
at ultranonography (US), VAT visceral adipose tissue at US; BSP blood systolic pressure; DBP diastolic blood pressure; SLD spleen longitudinal diameter at US; CRP
c reactive protein; g-GT gamma glutamyl transferase; ALT alanine aminotransferase; T2D type 2 diabetes mellitus; IFG impaired fasting glucose; MS metabolic
syndrome; IMT intima media thickness
Table 2 Relationship between obesity and hepatic
steatosis
Hepatic Steatosis Grade HS 1 HS 2 HS 3 Total
Obesity Grade 1 20 10 0 30
Obesity Grade 2 20 38 0 58
Obesity Grade 3 12 80 20 112
Total 52 128 20 200
Frequencies of obese patients throughout the grades [1-3] of HS, hepatic
steatosis
Figure 1 The behavior of heat shock protein-70 in Controls
and obese patients.
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HOMA values, hepatic IR does not seem to contribute to
peripheral IR. An early sign of atherosclerosis is hyper-
trophy of the arterial wall [35], even though circulating
HSP-70 has atheroprotective effects [36]. Accordingly, a
strict association between HSP-70 and HDL levels [37]
was found, even though an inverse correlation between
HSP-70 and IMT was lacking. Data from our series
showed that g-GT activity, although moderately corre-
lated to IR, was not different on the basis of the HS
severity. Interestingly, high g-GT levels were clearly asso-
ciated with hypertension, specifically with systolic values
(SBP), but not with increased IMT. The association
between CRP and early atherosclerosis is documented by
numerous works and CRP is recently proposed as cause
of the latter [38]. Our data point out on the strong corre-
lation between subcutaneous but not visceral adiposity
and CRP levels according to previous findings [39].
As limitations, we stress the followings. It has pre-
viously been shown that in dyslipidaemic and obese
i n d i v i d u a l st h e r ea r ee l e v a t e dt i t r e so fH S P sa n t i b o d i e s
[40], perhaps affecting the serum levels HSPs. In this
case, ageing should cause an increase of the circulating
levels of HSP-70 and not a decrease of the same ones
[8]. The assessment of HS severity could have been
more precise with liver biopsy even though US, as ima-
ging tool, is reliable for large scale studies [41].
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